* CareDx Inc CDNA.OQ CDNA.O is expected to show a rise
in
quarterly revenue when it reports results on May 3
(estimated).
* The Brisbane California California-based company is
expected to
report a 1.6% increase in revenue to $80.699 million from
$79.42 million a year ago, according to the mean estimate from 7
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for CareDx Inc is for a
loss
of 11 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 4.9%
in the last three months.
* Wall Street's median 12-month price target for CareDx Inc
is
$16, above its last closing price of $8.09.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.08 -0.09 -0.07 Beat 18.8
Sep. 30 2022 -0.14 -0.14 -0.06 Beat 57.1
Jun. 30 2022 -0.11 -0.11 -0.13 Missed -16.1
Mar. 31 2022 -0.05 -0.05 -0.13 Missed -160
Dec. 0.02 0.03 -0.03 Missed -192.3
31 2021
Sep. 30 2021 0.01 0.01 0.07 Beat 483.3
Jun. 30 2021 0.05 0.05 0.11 Beat 111.5
Mar. 31 2021 0.02 0.01 0.14 Beat 2,700
This summary was machine generated May 1 at 11:38 GMT. All
figures in US dollars unless otherwise stated